

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Bendamustine for the treatment of chronic lymphocytic leukaemia

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No equalities issues were raised during the scoping consultation process or at the scoping workshop.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

A submission raised the issue that the technology would not be suitable for patients who do not want to be treated by injection or by infusion. The Committee considered this was not a relevant issue according to the principles of the NICE Equality scheme because, in recommending bendamustine, NICE is not discriminating against any groups of people since bendamustine is available only as an intravenous infusion.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No equalities issues were raised by the Committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

This appraisal went straight to FAD: no preliminary recommendations were made.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

N/A

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

N/A an ACD was not produced as this appraisal went straight to FAD.

Approved by Associate Director: ...Frances Sutcliffe.....

Date: 21/02/2011

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

There was no consultation period as this appraisal went straight to FAD.

2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?
N/A	

3.	If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?
N/A	

4.	Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes, in the FAD table. This states that no equalities issues raised were thought to be relevant.	

Approved by Centre or Programme Director: Meindert Boysen

Date: 22/02/2011